These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 11006035)
1. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status. Fishman A; Dekel E; Chetrit A; Lerner-Geva L; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Piura B; Friedman E; Struewing JP; Modan B Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035 [TBL] [Abstract][Full Text] [Related]
2. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636 [TBL] [Abstract][Full Text] [Related]
3. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962 [TBL] [Abstract][Full Text] [Related]
4. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gotlieb WH; Chetrit A; Menczer J; Hirsh-Yechezkel G; Lubin F; Friedman E; Modan B; Ben-Baruch G; Gynecol Oncol; 2005 Jun; 97(3):780-3. PubMed ID: 15893369 [TBL] [Abstract][Full Text] [Related]
5. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794 [TBL] [Abstract][Full Text] [Related]
6. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492 [TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
8. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Roa BB; Boyd AA; Volcik K; Richards CS Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191 [TBL] [Abstract][Full Text] [Related]
9. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978 [TBL] [Abstract][Full Text] [Related]
10. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192 [TBL] [Abstract][Full Text] [Related]
11. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer. Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101 [TBL] [Abstract][Full Text] [Related]
12. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092 [TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Gershoni-Baruch R; Dagan E; Fried G; Kepten I; Robinson E Eur J Hum Genet; 1999; 7(7):833-6. PubMed ID: 10573018 [TBL] [Abstract][Full Text] [Related]
14. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881 [TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105 [TBL] [Abstract][Full Text] [Related]
16. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Beller U; Halle D; Catane R; Kaufman B; Hornreich G; Levy-Lahad E Gynecol Oncol; 1997 Nov; 67(2):123-6. PubMed ID: 9367693 [TBL] [Abstract][Full Text] [Related]
17. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464 [TBL] [Abstract][Full Text] [Related]
18. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients. Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560 [TBL] [Abstract][Full Text] [Related]
20. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]